Kuboki Yasutoshi, Mizunuma Nobuyuki
Dept. of Chemotherapy, Cancer Institute Ariake Hospital.
Gan To Kagaku Ryoho. 2007 Mar;34(3):380-6.
The number of elderly patients with colorectal cancer is increasing in Japan. Until recently, chemotherapy was not adapted for older patients. Today, older patients have opportunity to receive new regimen with newly developed agents and improvement of supportive therapy. UFT/leucovorin therapy has been shown to be as effective and equally tolerated in elderly patients as in younger patients. There is no difference between older and younger patients in efficacy and toxicity of FOLFOX 4 (oxaliplatin plus 5-FU and leucovorin) Bevacizumab with 5-FU and leucovorin is also tolerable and effective for elderly patients. It is necessary to evaluate the possibility of new molecular target agents for treatment for super-elderly patients (>80 years). Increasing cost of the new agents will pose economical problem to resolve specially for older population.
在日本，老年结直肠癌患者的数量正在增加。直到最近，化疗都不适用于老年患者。如今，老年患者有机会接受采用新研发药物的新治疗方案以及支持性治疗的改善。已证明优福定/亚叶酸钙疗法在老年患者中与年轻患者一样有效且耐受性相同。在FOLFOX 4（奥沙利铂加5-氟尿嘧啶和亚叶酸钙）的疗效和毒性方面，老年患者与年轻患者之间没有差异。贝伐单抗联合5-氟尿嘧啶和亚叶酸钙对老年患者也具有耐受性且有效。有必要评估新分子靶向药物用于治疗超高龄患者（>80岁）的可能性。新药成本的增加将带来经济问题，尤其对于老年人群体而言需要解决。
